The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial-Mesenchymal Transition.
Stefano ZapperiCaterina Anna Maria La PortaPublished in: International journal of molecular sciences (2023)
It would be highly desirable to find prognostic and predictive markers for triple-negative breast cancer (TNBC), a strongly heterogeneous and invasive breast cancer subtype often characterized by a high recurrence rate and a poor outcome. Here, we investigated the prognostic and predictive capabilities of ARIADNE, a recently developed transcriptomic test focusing on the epithelial-mesenchymal transition. We first compared the stratification of TNBC patients obtained by ARIADNE with that based on other common pathological indicators, such as grade, stage and nodal status, and found that ARIADNE was more effective than the other methods in dividing patients into groups with different disease-free survival statistics. Next, we considered the response to neoadjuvant chemotherapy and found that the classification provided by ARIADNE led to statistically significant differences in the rates of pathological complete response within the groups.
Keyphrases
- neoadjuvant chemotherapy
- epithelial mesenchymal transition
- end stage renal disease
- locally advanced
- lymph node
- ejection fraction
- free survival
- sentinel lymph node
- peritoneal dialysis
- chronic kidney disease
- signaling pathway
- prognostic factors
- transforming growth factor
- squamous cell carcinoma
- early stage
- patient reported outcomes
- deep learning
- single cell
- high speed
- atomic force microscopy